Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Olivier Michielin(SIB Swiss Institute of Bioinformatics), Ulrich Keilholz(German Cancer Research Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alexander C. J. van Akkooi(The University of Sydney), Reinhard Dummer(University Hospital of Zurich)
Cited by 621
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k